Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Drospirenone and Ethinyl Estradiol and Levomefolate Calcium Tablets, 3.0 mg/0.02 mg/0.451 mg and Levomefolate Calcium Tablets, 0.451 mg.
[More]
St. Michael's Hospital and King Saud University have received their first joint U.S. patent to use the BRCA1 gene as a therapy for cardiovascular disease.
[More]
Sanofi and Bristol-Myers Squibb Company announced today that Apotex has made payment in the amount of $442,209,362 to Sanofi and Bristol-Myers Squibb to satisfy the damages ruling of the Plavix (clopidogrel bisulfate) patent infringement case against Apotex.
[More]
Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has reached a settlement with Janssen Pharmaceuticals, Inc. on outstanding patent litigation related to Watson's generic version of Janssen's ORTHO TRI-CYCLEN LO (norgestimate/ethinyl estradiol) tablets.
[More]
ConforMIS, Inc. today announced it has completed its most productive period to date in the development of its intellectual property with the addition of 22 issued patents to its portfolio since January 2011.
[More]
United Therapeutics Corporation today announced receipt of a Paragraph IV Certification Notice Letter on February 3, 2012 from Sandoz Inc. advising that Sandoz has submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration requesting approval to market a generic version of the 10 mg/mL strength of Remodulin (treprostinil) injection.
[More]
Precision BioSciences, Inc., a leader in the field of genome engineering, today announced that the United States Patent and Trademark Office (PTO) has issued Notices of Allowance for U.S. Patent Applications 13/246,270 and 13/246,346.
[More]
In response to investment community speculation following release of the transcript of a pre-trial conference call related to its Lidoderm patent challenge, Watson Pharmaceuticals, Inc. today issued the following statement: Watson's abbreviated new drug application (ANDA) for a generic version of Lidoderm remains on track.
[More]
BodyMedia, Inc., the leader in wearable body monitors, announced today that it has filed a patent infringement suit against BASIS Science, Inc. in the U.S. Federal District Court in Delaware for willfully infringing BodyMedia's breakthrough patented wearable body monitoring devices and sensor fusion technology.
[More]
ImmunoCellular Therapeutics, Ltd., a biotechnology company focused on the development of novel immune-based cancer therapies, announced the allowance of U.S. patent claims related to the Company's method of treating glioblastoma multiforme (GBM) in a patient by targeting cancer stem cells.
[More]